Abstract: Primary infection with the human oncogenic Epstein-Barr virus (EBV) can result in infectious mononucleosis (IM), a self-limiting disease caused by massive lymphocyte expansion that predisposes for the development of distinct EBV-associated lymphomas. Why some individuals experience this symptomatic primary EBV infection, whereas the majority acquires the virus asymptomatically, remains unclear. Using a mouse model with reconstituted human immune system components, we show that depletion of human natural killer (NK) cells enhances IM symptoms and promotes EBV-associated tumorigenesis mainly because of a loss of immune control over lytic EBV infection. These data suggest that failure of innate immune control by human NK cells augments symptomatic lytic EBV infection, which drives lymphocyte expansion and predisposes for EBV-associated malignancies. 
INTRODUCTION
Epstein-Barr virus (EBV) is carried as a persistent infection by more than 90% of the human adult population (Young and Rickinson, 2004) . Whereas most individuals acquire the virus asymptomatically, up to 10% develop infectious mononucleosis (IM), especially when primary infection is delayed into adolescence (Balfour et al., 2013; Kutok and Wang, 2006; Luzuriaga and Sullivan, 2010 ). This disease is accompanied by high EBV titers and massive lymphocytosis, primarily by EBV-specific CD8 + T cells targeting viral antigens that are involved in infectious particle production, called lytic infection (Hislop et al., 2007; Odumade et al., 2012) . During the first 5 years after resolution of IM symptoms an increased risk to develop EBV-associated classical Hodgkin lymphoma is observed (Hjalgrim et al., 2003) . EBV viremia, possibly driving EBV-specific CD8 + T cell expansion and tumorigenesis, could result from insufficient innate immune control of EBV, and indeed frequencies or counts for the innate lymphocytes natural killer (NK) cells were found to either inversely or directly correlate with EBV titers in infectious mononucleosis (Balfour et al., 2013; Williams et al., 2005) . Further arguing for a role of NK cells in EBV-specific immune control, primary immunodeficiencies that affect NK cells or NK cell recognition of EBV-transformed B cells have been reported to be associated with EBV-positive malignancies and high susceptibility to EBV (Eidenschenk et al., 2006; Parolini et al., 2000; Shaw et al., 2012) . Because experimental in vivo models for dissecting the pathogenesis of this human B cell tropic herpes virus or close relatives are rare (Melkus et al., 2006; Sashihara et al., 2011; Traggiai et al., 2004; Yajima et al., 2008) , addressing and manipulating specific parameters of the immune response to EBV remained difficult. In order to characterize the role of NK cells during primary EBV infection, we investigated NOD-scid g c À/À mice with reconstituted human immune system components (huNSG mice), which constitute a suitable in vivo model for human NK cell responses and EBV infection as well as virusspecific immune control (Rä mer et al., 2011; Shultz et al., 2010; Strowig et al., 2009 Strowig et al., , 2010 White et al., 2012; Yajima et al., 2009) .
RESULTS

Human NK Cells Dampen Immunophenotype during EBV Infection
Human and mouse NK cells specifically express NKp46 (Pessino et al., 1998; Walzer et al., 2007) , and the majority of human NK cells of huNSG mice are positive for NKp46 as well (Strowig et al., 2010) . Therefore, the NKp46-specific monoclonal antibody BAB281 was used for NK cell depletion. This treatment significantly diminished both CD3
À
NKp46
+ and CD3 À CD56 + cell populations in treated mice (Figures S1A and S1B), whereas an isotype control antibody neither altered the composition of the reconstituted human immune system compartments nor the course of infection (data not shown). Infection of huNSG mice via intraperitoneal inoculation with 1 3 10 5 Raji-infecting units (RIU) of B95-8 EBV resulted in increased CD8 + T cells frequencies and total numbers in both spleen and blood over the 6-week course of infection ( Figures 1A-1D ). This characteristic feature of acute IM was significantly more pronounced in NKcell-depleted animals ( Figures 1A-1D ) and was accompanied with nearly 10-fold elevated serum levels of IFN-g ( Figure 1E ). Moreover, in animals depleted of human NK cells, IFN-g mRNA expressed in CD4 + T cells was also significantly increased, reaching expression similar to CD8 + T cells in nondepleted animals after infection (Figures 1F and 1G) . The splenomegaly, resulting from EBV-stimulated CD8 + T cell expansion, was enhanced in the absence of NK cells ( Figure 1H ). Thus, prominent features of symptomatic primary EBV infection in humans, i.e., acute IM, can be modeled in huNSG mice and are strongly pronounced in animals depleted of human NK cells.
Human CD8 + T Cells Display an Activated Memory Phenotype after EBV Infection
In order to characterize the IM-like T cell expansion after EBV infection of NK-cell-depleted huNSG mice further, we phenotyped their CD4 + and CD8 + T cells. Activated memory T cells were mainly found within the CD8 + T cell compartment in infected animals (Figures S2A and S2B) and expanded at the cost of naive CD8 + T cell frequencies with NK cell depletion significantly affecting CX3CR1 upregulation and expansion of CD11a + CD127
À CD8 + T cells, which in mice have been proposed to be short-lived effector cells (Kaech et al., 2003) (Figures S2C and S2D) . Inhibitory receptors and terminal differentiation markers on CD8 + T cells were also significantly upregulated upon EBV infection, exclusively on cells coexpressing the memory marker CD45RO ( Figure S2E ). Still CD8 + T cells displayed high levels of the effector molecules perforin and granzyme B with the latter significantly more expressed in animals depleted of NK cells ( Figure S2F ). Despite this terminal differentiation phenotype of CD8 + T cells during EBV infection of NK-cell-depleted mice, these CD8 + T cells were still able to exert considerable control over viral titers in NK-cell-depleted animals, because CD8 + T cell depletion on top of NK cell depletion led to one log increased viral loads in blood and spleen (Figures 1I and 1J ; for depletion efficiency, see Figures S1C and S1D). Thus, a highly activated, but still protective, CD8 + T cell phenotype that mimics the one seen in IM in humans (Hislop and Sabbah, 2008; Odumade et al., 2012) could be observed during EBV infection in huNSG mice, especially after human NK cell depletion. (Figure 2  C ). This NK cell expansion or enhanced recruitment to the blood was followed by a contraction of NK cell frequencies in both the periphery and spleen (Figures 2A, 2B , and S3A). Human NK cells 6 weeks postinfection did not significantly proliferate as indicated by staining for the proliferation marker as has been described for NK cells in human acute IM (Zhang et al., 2007) and only slightly upregulated the activation marker CD69 ( Figure 2E ) compared to the robust upregulation for both CD69 and Ki-67 on human CD8 + T cells (Figures 2E and S3B, respectively) . Frequencies of more differentiated CD16 + NK cells were still elevated ( Figure 2D ), but the majority remained NKG2A positive and killer immunoglobulin-like receptor (KIR) negative (Figures 2E and 2F 
EBV Infection Drives an
Human NK Cells Control Viral Load and Prevent EBV-Induced Malignancy
The functional relevance of this NK cell subset accumulation became apparent from the analysis of viral titers in animals depleted of human NK cells. NK cells control EBV infection in huNSG mice, because cell-associated viral titers in both spleen and blood were increased one log 5 to 6 weeks postinfection in the absence of NK cells (Figures 3A and 3B) . Infected animals depleted of NK cells showed a dramatic loss of body weight ( Figure 3C ) as well as a significantly higher incidence of infiltrative lymphomatous tumors at multiple sites Figure S4A) , which were mostly monoclonal ( Figures S4B-S4D ) compared to infected nondepleted animals. However, when NK cells were further expanded and differentiated to express CD16, KIRs, and CD57 through cytokine-treatment driven expansion and differentiation, they controlled EBV infection less well ( Figure S5 ). These data indicate that especially human NK cells with an early differentiation phenotype control viral load and prevent detrimental cancerous sequelae of infection in the host.
Human NK Cells Primarily Respond to Lytic EBV Infection Given that, during IM primarily lytic EBV, antigen-specific CD8 + T cells expand (Hislop et al., 2007) , the differential regulation of latent, i.e., cell proliferation inducing, versus lytic viral replication by NK cells was analyzed. Intriguingly, viral copy numbers in plasma of NK-cell-depleted animals were more dramatically increased than in whole blood, up to 100-fold 5 and 6 weeks postinfection ( Figure 4A ). This led us to investigate whether signs of lytic infection were more readily observed in the absence of NK cells. Indeed, BZLF-1-one of the two immediate early transactivators of EBV lytic cycle induction and indicator of lytic infection-and the late lytic antigen VCA p40 were expressed at increased levels in spleen sections from NK-cell-depleted animals ( Figure 4B ). Consistent with a higher availability of lytic EBV antigens, splenocytes of NK-cell depleted and infected animals recognized latently EBV-infected autologous B cell lines (LCLs) significantly less well by IFN-g production than nondepleted controls ( Figure 4C ), and some mice carried slightly elevated CD8 + T cell populations that stained with MHC class I dextramers carrying lytic EBV antigen derived peptides ( Figure S6 ). To confirm targeting of lytic infection by NK cells in vitro, we used AKBM cells that can be induced to enter the lytic cycle ( Figure 4D ). As reported, lytic AKBM cells showed decreased expression of MHC class I molecules (Pappworth et al., 2007) ( Figure 4E ) and as a surrogate for cytotoxicity elicited more degranulation of NK cells derived from EBV-infected animals than from latent AKBM cells (Figure 4F) . This preferential recognition of lytically EBV-replicating B cells had been previously described for peripheral blood human NK cells in vitro (Pappworth et al., 2007) . Altogether, these data suggest that NK cells preferentially respond to lytically infected cells, and one reason for this might be loss of inhibitory signals delivered by MHC class I molecules on the target cells.
Latent EBV Infection Is Unaffected by Human NK Cells
To test our hypothesis that NK cell preferentially restrict lytic EBV infection in vivo, we infected animals with 1 3 10 5 RIU BZLF-1 knockout (KO) B95-8 virus, which is unable to switch to lytic replication and therefore can only establish the default program of latent EBV infection. Indeed, no significant weight loss or difference in tumor formation was observed after KO virus infection, regardless of the presence or absence of NK cells ( Figures 5A and 5B). Viral titers in spleen ( Figure 5C ) and whole blood ( Figure 5D ) were not significantly affected by NK cell depletion 6 weeks postinfection. In contrast, a revertant virus, in which BZLF-1 was reinserted into the BZLF-1 KO EBV, replicated to higher blood and splenic viral titers in the absence of NK cells ( Figure S7 ), and therefore behaved similar to the wild-type virus infection. Interestingly, immunoactivation of the T cell compartment and development of splenomegaly after BZLF-1 KO EBV infection was almost similar to wild-type EBV infection for both NK-cell-depleted and nondepleted animals ( Figure S8 ), confirming the potency of the KO virus. However, whereas a significant reduction of NK cells 6 weeks postinfection could still be observed in blood ( Figures 
DISCUSSION
Our study suggests that loss of NK-cell-mediated immune control over lytic EBV infection allows this human tumor virus to replicate to higher titers, driving lymphocytosis and promoting predisposition for EBV-associated lymphoma development. These are IM-like symptoms and known sequelae of IM (Hjalgrim et al., 2003) , and the monoclonality of the emerging tumors as well as the associated weight loss argue for manifestations of fatal IM (Brown et al., 1986; Wick et al., 2002) . NK cells might act only late during the course of infection in our model, because EBV first establishes default latent infection of B cells after intraperitoneal injection. Lytic replication is then only later reactivated from this latent pool to produce virus particles for increased B cell transformation and/or conditioning of the microenvironment for tumor growth (Hong et al., 2005; Ma et al., 2011) . Only this delayed lytic replication seems to be restricted by human NK cells in huNSG mice. (Bihl et al., 2010; Horowitz et al., 2010) . Our data support such a prolonged immune control by NK cells during viral infections and suggest that human NK cells of an early differentiation phenotype selectively restrict lytic EBV replication. Instead of CD8 + T cell expansion by elevated viral titers, caused by uncontrolled lytic replication, human T cell expansion could, however, also result from loss of direct NK cell cytotoxicity toward activated T cells, as has been suggested in mice (Lang et al., 2012; Waggoner et al., 2012) . In favor of this interpretation, we also observed T cell expansion-albeit weaker-upon BZLF-1 knockout virus infection in NK-cell-depleted huNSG mice, without significant changes in EBV viremia. Therefore, NK cells might be involved in the prevention of IM by limiting viral antigen load that would otherwise drive massive T cell expansion and by restricting antiviral T cell expansion directly via cytotoxic restriction of activated T cells-in a possibly perforin-dependent + NK cells in blood and spleen 6 weeks p.i. in nondepleted animals (n = 9, mean ± SEM, one representative experiment for spleen). (legend continued on next page) manner-as has been previously reported (Lang et al., 2012; Waggoner et al., 2012) . These two scenarios do not need to be mutually exclusive but might indeed complement each other. Altogether, these data suggest that low NK cell reactivity-as shown for the association with increased cancer risk (Imai et al., 2000) -might identify EBV seronegative individuals at risk to develop IM, for which EBV vaccination could be developed.
EXPERIMENTAL PROCEDURES
Mice NOD/LtSz-scid IL2Rg null (NOD-scid g c À/À or NSG) and HLA-A2 transgenic NSG (NSG-A2) mice were obtained from the Jackson Laboratory and bred and maintained at the Institute of Experimental Immunology, University of Zü rich, under specific pathogen-free conditions. Newborn NSG mice (1 to 5 days old) were irradiated with 1 Gy using a Cs source. Five to six hours after irradiation, mice were injected intrahepatically with 1-2 3 10 5 CD34 + human hematopoietic progenitor cells derived from human fetal liver tissue obtained from Advanced Bioscience Resources. Preparation of human fetal liver tissue and isolation of human CD34 + cells was done as described previously (Strowig et al., 2009 (Strowig et al., , 2010 White et al., 2012 RIUs with the respective viruses and followed for 6 weeks. Depletion of NK cells in huNSG mice was done via intraperitoneal injection of purified anti-NKp46 (clone BAB281) in PBS on three consecutive days (total of 300 mg per mouse). On the following day, depletion efficiency was determined in peripheral blood by flow cytometry (Figures S1A and S1B), and animals were infected by inoculation via intraperitoneal injection of 1 3 10 5 RIU EBV. CD8 + T cells were depleted with purified anti-CD8 (clone OKT-8, Bio X Cell) diluted in PBS via intraperitoneal injection on three consecutive days (total of 150 mg per mouse) before infection and again 2 weeks postinfection every second day (50 mg per mouse each application).
Flow Cytometry
All fluorescently labeled antibodies were purchased from BD Biosciences, BioLegend, Invitrogen, and R&D Systems. Spleens were mechanically disrupted and filtered through a 70 mm cell strainer before separation of mononuclear cells on Ficoll-Paque gradients. Lysis of erythrocytes in whole blood was done with NH 4 Cl. Dextramer staining was performed in accordance with the manufacturer's instructions (Immudex). For intracellular staining, the Cytofix/ Cytoperm Kit from BD Biosciences was used. Cell suspensions were stained with antibodies for 30 min on ice, washed, and analyzed on FACSCanto or LSR Fortessa cytometers (BD Biosciences). Analysis of flow cytometric data was performed with FlowJo (Tree Star).
Quantification of Viral Load
Total DNA from whole blood or plasma was extracted using the QIAmp Mini Kit (Qiagen) in accordance with the manufacturer's instructions. Splenic tissue (5-15 mg) was processed using the QIAmp Tissue Kit (Qiagen) in accordance with the manufacturer's protocol. DNA was eluted in 50 ml Tris-EDTA and stored at 4 C. Quantitative analysis of EBV DNA was performed by a TaqMan (Applied Biosystems) real-time PCR technique as described previously (Berger et al., 2001) ELISA Detection of human IFN-g in serum from huNSG mice was performed with a human IFN-g ELISA Kit (Mabtech) in accordance with the manufacturer's instructions.
Quantitative Real-Time PCR Total RNA was extracted using the RNeasy Micro Kit (Qiagen) in accordance with the manufacturer's instructions. Complementary DNA was reverse transcribed using the GoScript Reverse Transcription System (Promega). Primers and probes were predesigned Taqman Gene Expression Assays (Applied Biosystems, IFN-g: Hs00989291_m1 and 18S: Hs99999901_s1). Real-time PCR was performed on a CFX384 Touch Real-Time PCR Detection System (Bio-Rad) machine. All samples were run in triplicates and normalized using 18S expression level.
AKBM Cells and Degranulation Assay
EBV-positive AKBM cells that express GFP upon switch from latent to lytic EBV replication were induced to enter the lytic cycle after ligation with F(ab) IgG. BZLF-1 and HLA class I expression was monitored after intracellular staining for BZLF-1 (BZ-1, Santa Cruz Biotechnology) and surface staining for HLA-ABC (w6/32), respectively. For the degranulation assay, splenic cell suspensions and induced (lytic) or noninduced (latent) AKBM cells were cocultured at a ratio of 1:1 for 5 hr with addition of monensin after 1 hr, and NK cells were then analyzed for expression of the degranulation marker CD107a.
Statistical Analysis
All data were analyzed with a two-tailed Student's t test unless otherwise stated. A p value of < 0.05 was considered statistically significant. Statistical analysis and generation of graphs was performed with Prism software (GraphPad). provided crucial reagents. O.C. and C.M. designed the overall research and wrote the manuscript.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES Histology and immunohistochemistry
Tissue was fixed in 10% saline buffered formalin and paraffin embedded. For immunohistochemistry, mouse and rabbit anti-human monoclonal antibodies (all from Dako or Zytomed) were used and 4 µm sections processed using standard procedures on a BOND-MAX automated immunohistochemistry system (Leica Microsystems) with appropriate positive and negative controls. Antibody against EBNA1 (clone 1H4) was a gift from Dr. Kremmer. To identify lytic virus infection, IHC with antibodies directed against the BZLF1 immediate early protein (clone BZ1, Santa
Cruz) and against the EBV p40 protein of the VCA complex (clone OT41, kind gift from Prof. J. Middeldorp) was used. EBV infection was determined by in situ hybridization (ISH) with digoxigenin-conjugated probes for EBV-encoded RNAs (EBER-ISH) (Meyer et al., 2011) or an EBER-1 probe developed with alkaline phosphatase on a BOND-MAX automated system.
As described previously for quantitative evaluation of labeled cells (Barros et al., 2012) , each tissue core was photographed using AxioCam MRc camera (Zeiss) at a 200x magnification. The numbers of labeled cells were determined per 1 mm 2 using the image analysis software HISTO (Biomas). The markers related to EBV infection and immune cells were quantified in the spleen and/or in the peri-pancreatic lymph nodes but not in extra-lymphatic tissues.
In both non-depleted and NK cell-depleted mice, marked proliferation of pleomorphic immunoblasts was observed. These immunoblasts were uninucleated, 
Analysis of clonality
DNA was extracted from 5 µm-sections of paraffin embedded tissue, following strict measures for avoiding cross-contamination between samples as described (Stefanoff et al., 2003) . DNA was quantified using a Nanodrop® spectrophotometer and approximately 100 ng of DNA was used for PCR testing. All samples were shown to be PCR amplifiable for a human constitutive gene (β-globin) and an EBV specific gene heteroduplex formation was promoted by denaturing PCR products at 94°C for 5 min followed by renaturation at 4ºC for 60 min. Products were electrophoresed in 8% nondenaturing polyacrylamide gels and silver stained. For fluorescent detection, the same procedures were performed, using 6'FAM-labeled JH primers. PCR products (1 µl)
were mixed with 9.5 µl Hi-Di formamide, and 0.5 µl of LIZ fluorescent internal size standard. Electrophoresis was performed in a capillary sequencer 3130XL (Applied Biosystems) with POP7 polymer. Analysis was performed with the GeneMapper version 4.0 software.
To determine the clonality of a PCR product, a peak-height ratio was calculated as the ratio of peak heights between a 'clonal' prominent peak and the average of the two adjacent peaks. A PCR product was defined as monoclonal in the case of 1-2 sharp peaks yielding a peak-height ratio >2. An oligoclonal pattern was defined as a nonGaussian distribution of three or more prominent peaks. Polyclonality was defined in the presence of multiple peaks with a Gaussian distribution. Multiple peaks with a nonGaussian distribution were classified as skewed polyclonal. All results were confirmed in the same sample on two repeated runs.
Cytokine treatment
Cytokine treatment with IL-2 formulations (compound 1 and compound 2) or IL-15 complexes was done i.p. with a total of 75000 I.U. over five consecutive days as described (Krieg et al., 2010) and analysis one day after the last treatment or infection with EBV for IL-2 compound 1.
